<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Although Osteosarcoma (OS) is a rare disease comprising less than 1% of cancers diagnosed in the United States, it is the most common primary malignant bone tumor in adolescents and young adults. OS accounts for 8.9% of cancer-related deaths and carry an overall 5-year survival rate of 60â€“70% despite modern treatment protocols that combine chemotherapy and surgery [
 <xref rid="B6-marinedrugs-16-00504" ref-type="bibr" class="xref">6</xref>,
 <xref rid="B7-marinedrugs-16-00504" ref-type="bibr" class="xref">7</xref>]. Chemotherapy has been established as a critical component of OS therapy, but its adverse side effects associated with the drug resistance developed by tumors, lead to the urgent need for new and specific anticancer agents.
</p>
